Temple report followup audit
This article was originally published in The Gray Sheet
Executive SummaryFDA device center begins internal review of "a sample of targeted and randomly selected" device applications to determine the prevalence of data deficiencies identified in the recent Committee for Clinical Review report, according to a June 15 memo to device center staffers. FDA announced plans to conduct the more in-depth audit when the Temple report was released in March ("The Gray Sheet" March 8, p. 1).
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.